Table 1. Baseline characteristics of Sjögren’s syndrome cohort.
| Entire cohort (n = 4,262) | One-year Landmark cohort | Three-year landmark cohort | |||||
|---|---|---|---|---|---|---|---|
| Included patients (n = 4,194) | Excluded patients (n = 68) | P value | Included patients (n = 4,066) | Excluded patients (n = 196) | P value | ||
| Age (years) | |||||||
| Median (interquartile range) | 53 (44–63) | 53 (44–63) | 62 (51–72) | <.0001a | 52 (43–63) | 66 (53–74) | <.0001a |
| Gender, No. (%) | |||||||
| Men | 573 (13.44) | 556 (13.26) | 17 (25.00) | 0.0049 | 524 (12.89) | 49 (25.00) | <.0001 |
| Women | 3689 (86.56) | 3638 (86.74) | 51 (75.00) | 3542 (87.11) | 147 (75.00) | ||
| Place of residence, No. (%) | |||||||
| Urban | 1388 (32.57) | 1368 (32.62) | 20 (29.41) | 0.5578 | 1322 (32.51) | 66 (33.67) | 0.8337 |
| Suburban | 1295 (30.38) | 1273 (30.35) | 22 (32.35) | 1239 (30.47) | 56 (28.57) | ||
| Rural | 1484 (34.82) | 1458 (34.76) | 26 (38.24) | 1413 (34.75) | 71 (36.22) | ||
| Unknown | 95 (2.23) | 95 (2.27) | -- | 92 (2.26) | 3 (1.53) | ||
| Income level, No. (%) | |||||||
| Quintile 1 | 849 (19.92) | 832 (19.84) | 17 (25.00) | 0.2303 | 800 (19.68) | 49 (25.00) | 0.0553 |
| Quintile 2 | 453 (10.63) | 449 (10.71) | 4 (5.88) | 436 (10.72) | 17 (8.67) | ||
| Quintile 2 | 1024 (24.03) | 1002 (23.89) | 22 (32.35) | 967 (23.78) | 57 (29.08) | ||
| Quintile 4 | 738 (18.37) | 775 (18.48) | 8 (11.76) | 759 (18.67) | 24 (12.24) | ||
| Quintile 5 | 1100 (25.81) | 1083 (25.82) | 17 (25.00) | 1052 (25.87) | 48 (24.49) | ||
| Unknown | 53 (1.24) | 53 (1.26) | -- | 52 (1.28) | 1 (0.51) | ||
| Occupation, No. (%) | |||||||
| Dependents of the insured individuals | 1025 (24.05) | 1005 (23.96) | 20 (29.41) | 0.0914 | 959 (23.59) | 66 (33.67) | <.0001 |
| Civil servants, teachers, military personnel, and veterans | 397 (9.31) | 395 (9.42) | 2 (2.94) | 390 (9.59) | 7 (3.57) | ||
| Nonmanual workers and professionals | 1000 (23.46) | 990 (23.61) | 10 (14.71) | 976 (24.00) | 24 (12.24) | ||
| Manual workers | 1401 (32.87) | 1375 (32.78) | 26 (38.24) | 1332 (32.76) | 69 (35.20) | ||
| Other | 439 (10.30) | 429 (10.23) | 10 (14.71) | 409 (10.06) | 30 (15.31) | ||
| Charlson comorbidity index, No. (%) | |||||||
| 1–2 | 3221 (75.57) | 3187 (75.99) | 34 (50.00) | <.0001 | 3111 (76.51) | 110 (56.12) | <.0001 |
| 3–4 | 533 (12.51) | 517 (12.33) | 16 (12.53) | 497 (12.22) | 36 (18.37) | ||
| ≥ 4 | 508 (11.92) | 490 (11.68) | 18 (26.47) | 458 (11.26) | 50 (25.51) | ||
| Medications, No. (%) | |||||||
| Azathioprine | 29 (0.68) | 28 (0.67) | 1 (1.47) | 0.3737b | 27 (0.66) | 2 (1.02) | 0.3881b |
| Prednisolone | 1993 (46.76) | 1956 (46.64) | 37 (54.41) | 0.2025 | 1901 (46.75) | 92 (46.94) | 0.9595 |
| Methotrexate | 35 (0.82) | 35 (0.83) | -- | 1.0000b | 34 (0.84) | 1 (0.51) | 1.0000b |
| Cyclosporin | 11 (0.26) | 10 (0.24) | 1 (1.47) | 0.1623b | 9 (0.22) | 2 (1.02) | 0.0881b |
aWilcoxon rank sum test.
bFisher’s Exact Test.